I jotted down a few brief notes along the way and below is my...

I jotted down a few brief notes along the way and below is my understanding of what was said. No liability accepted for accuracy.

The presentation basically was the standard spiel except Graham updated the Burns and Sepsis trials information, which he admitted included price sensitive information. Hence the presentation slides were released immediately afterwards as a price sensitive announcement. I should think some confirmation of the points below will appear in the 4C report.

Graham currently is in Perth for clinical trial purposes.

There is no foreseen need for any raising of capital.

He expects a lot to happen over the next four months.

A new clinical efficacy study will be announced that appears to relate to a particular target bacterium. (Perhaps helicobacter pylori, which would fit the timing of the Sutton appointment??)
  
The Sepsis trial is currently dosing at 6000mg and this will complete Phase 1. There is no need to go further as we already are well within the effective dose range. Preparations for a new Phase study are already underway.

The Burns trial appears to be complete, has been very successful, and the study data is now under review for next step considerations.

Graham was very positive, with his usual ‘wink wink’ attitude.